Search

Your search keyword '"Gudgeon, Anne"' showing total 10 results
Start Over Author "Gudgeon, Anne"
10 results on '"Gudgeon, Anne"'

3. Identifying Breast Cancer Patients at High Risk for Bone Metastases

Author

Colleoni, Marco, O’Neill, Anne, Goldhirsch, Aron, Gelber, Richard D., Bonetti, Marco, Thürlimann, Beat, Price, Karen N., Castiglione-Gertsch, Monica, Coates, Alan S., Lindtner, Jurij, Collins, John, Senn, Hans-Jörg, Cavalli, Franco, Forbes, John, Gudgeon, Anne, Simoncini, Edda, Cortes-Funes, Hernan, Veronesi, Andrea, Fey, Martin, and Rudenstam, Carl-Magnus

Published
2000

4. Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients With Breast Cancer: The International Breast Cancer Study Group Trial VII

Author

Crivellari, Diana, Bonetti, Marco, Castiglione-Gertsch, Monica, Gelber, Richard D., Rudenstam, Carl-Magnus, Thürlimann, Beat, Price, Karen N., Coates, Alan S., Hürny, Christoph, Bernhard, Jürg, Lindtner, Jurij, Collins, John, Senn, Hans-Jörg, Cavalli, Franco, Forbes, John, Gudgeon, Anne, Simoncini, Edda, Cortes-Funes, Hernan, Veronesi, Andrea, Fey, Martin, and Goldhirsch, Aron

Published
2000

6. Present and future projects of the International Breast Cancer Study Group

Author

Goldhirsch, Aron, Gelber, Richard D., Castiglione, Monica, Price, Karen N., Rudenstam, Carl-Magnus, Lindtner, Jurij, Collins, John, Senn, Hans-Jorg, Brunner, Kurt W., Galligioni, Enzo, Cavalli, Franco, Gudgeon, Anne, Cortes-Funes, Hernan, Tattersall, Martin, Marini, Giovanni, Byrne, Michael, Snyder, Ray, Forbes, John F., Hurny, Christoph, and Coates, Alan

Subjects
Breast cancer -- Adjuvant treatment, Chemotherapy -- Research, Health
Abstract

The International Breast Cancer Study Group formerly the adjuvant Group) has conducted nine clinical trials since 1978 (see the Appendix for participants and authors). Biologic hypotheses related to the combined use of chemotherapy and endocrine therapy in women with operable breast cancer were tested. Questions of timing of chemotherapy with respect to tumor surgery and late introduction of chemotherapy were also evaluated. Ongoing and future trials continue in this tradition to investigate combinations of available endocrine therapies and cytotoxic agents. Cancer 1994; 74:1139-49. Keywords: breast cancer, adjuvant therapy, clinical trials, chemotherapy, endocrine therapy, chemoendocrine therapy. tamoxifen, cyclophosphamide-methotrexate-5-fluorouracil.

Published
1994

9. Risk of Breast Cancer in Relation to the Use of Injectable Progestogen Contraceptives and Combined Estrogen/Progestogen Contraceptives.

Author

Shapiro, Samuel, Rosenberg, Lynn, Hoffman, Margaret, Truter, Hanneke, Cooper, Diane, Rao, Sowmya, Dent, David, Gudgeon, Anne, Zyl, Jakobus van, Katzenellenbogen, Judith, and Bailie, Ross

Subjects
BREAST cancer risk factors, SIDE effects of oral contraceptives, SYNTHETIC progestagens, ESTROGEN, CONTRACEPTIVES, CASE-control method, WOMEN'S health, EPIDEMIOLOGY of cancer
Abstract

Recent studies have suggested that progestogen-only contraceptives and combined estrogen/progestogen oral contraceptives (COCs) may increase the risk of breast cancer among women less than 35 years of age or among recent users, The authors conducted a case-control study, in which cases of breast cancer (n = 419) and controls (n = 1,625) hospitalized for conditions unrelated to contraceptive use were interviewed from 1994 to 1997 in hospitals in greater Cape Town, South Africa. The women were aged 20–54 years, resided in a defined area around Cape Town, and were Black or of mixed racial descent. The relative risk for exposure to injectable progestogen contraceptives (IPCs), mostly depot medroxyprogesterone acetate, was 0.9 (95% confidence interval (CI) 0.7, 1.2). There were no consistent associations within categories of age or recency or duration of use. For exposure to COCs, the overall relative risk was 1.2 (95% CI 1.0, 1.5). Among women below age 35 years, the relative risk was 1.7 (95% CI 1.0, 3.0), and it was unrelated to the duration or recency of use. The findings suggest that IPCs do not increase the risk of breast cancer, and that COCs may increase the risk among women below age 35 years, although bias cannot be excluded. Am J Epidemiol 2000;151:396–403. [ABSTRACT FROM PUBLISHER]

Published
2009

10. Screening for breast cancer.

Author

Edge J and Gudgeon A

Subjects
Age Factors, Aged, Female, Humans, Mass Screening organization & administration, Middle Aged, Patient Compliance, Risk Assessment, Sensitivity and Specificity, South Africa, Breast Neoplasms prevention & control, Breast Self-Examination, Mammography methods
Published
2004

Catalog

Books, media, physical & digital resources
See catalog results